Literature DB >> 18524791

Familial aggregation of psoriatic arthritis.

V Chandran1, C T Schentag, J E Brockbank, F J Pellett, S Shanmugarajah, S M A Toloza, P Rahman, D D Gladman.   

Abstract

OBJECTIVES: The aim of this study was to determine the recurrence risk of psoriatic arthritis (PsA) and uncomplicated psoriasis in first-degree relatives (FDRs) of patients with PsA.
METHODS: All available FDRs (full siblings, parents and children) of 100 consecutive consenting patients attending a PsA clinic were evaluated for the presence of psoriasis and PsA using a standard protocol. The protocol included a screening questionnaire, physical examination by a rheumatologist, and radiographic and laboratory assessment. The prevalence of PsA and psoriasis in FDRs of the index cases was determined, and the recurrence risk ratio (lambda) was calculated, assuming a population prevalence of PsA of 0.25%, and a population prevalence of psoriasis of 2%.
RESULTS: The 100 probands had 533 relatives. Eighty-four of them were deceased and 53 were unavailable (age <16 years). Of the remaining 396 FDRs, 107 did not participate (living too far away/did not consent). Thus, 289/396 (73%) of the available FDRs participated in the study. There were 130 siblings, 108 parents and 51 children. The prevalence of PsA and psoriasis among FDRs was 7.6% and 15.2%, respectively. The lambda(1 )was 30.4 for PsA and 7.6 for psoriasis. The prevalence of PsA and psoriasis in siblings was 7.7% and 17.7%, respectively. The lambda(S) was 30.8 for PsA and 8.8 for psoriasis.
CONCLUSIONS: The recurrence risk ratio for both PsA and psoriasis is high in FDRs and siblings of patients with PsA. These results confirm that both PsA and psoriasis have a strong heritable component.

Entities:  

Mesh:

Year:  2008        PMID: 18524791     DOI: 10.1136/ard.2008.089367

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  46 in total

1.  [Genetics of common chronic inflammatory skin diseases : An update on atopic dermatitis and psoriasis].

Authors:  E Rodríguez; K Eyerich; S Weidinger
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

Review 2.  The genetics of psoriasis and psoriatic arthritis.

Authors:  Vinod Chandran
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 3.  What have genome-wide studies told us about psoriatic arthritis?

Authors:  James Bluett; Anne Barton
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 4.  Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotype?

Authors:  William Tillett; Neil McHugh
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

5.  Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need.

Authors:  Alexis Ogdie; Joel M Gelfand
Journal:  Arch Dermatol       Date:  2010-07

Review 6.  Genetics of susceptibility and treatment response in psoriatic arthritis.

Authors:  Darren D O'Rielly; Proton Rahman
Journal:  Nat Rev Rheumatol       Date:  2011-11-08       Impact factor: 20.543

Review 7.  Where do we stand with the genetics of psoriatic arthritis?

Authors:  Darren D O'Rielly; Proton Rahman
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

8.  Deletion of late cornified envelope genes, LCE3C_LCE3B-del, is not associated with psoriatic arthritis in Tunisian patients.

Authors:  Bouchlaka Souissi Chiraz; Ammar Myriam; Zarra Ines; Jordan Catherine; Bouazizi Fatma; Cheour Ilhem; Tekaya Raoudha; Zeglaoui Hela; Fourati Hela; Bouajina Elyes; Doss Nejib; Helms Cindy; Elgaaied Amel; Sellami Slaheddine
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

9.  Which Psoriasis Patients Develop Psoriatic Arthritis?

Authors:  Kristine Busse; Wilson Liao
Journal:  Psoriasis Forum       Date:  2010

10.  Genetics of psoriasis and psoriatic arthritis.

Authors:  Vinod Chandran
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.